Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MLAB
stocks logo

MLAB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q4
FY2027Q1
63.23M
+0.63%
0.277
-189.25%
64.47M
+3.75%
0.353
-126.97%
62.65M
+5.22%
0.325
-61.76%
Estimates Revision
The market is revising Downward the revenue expectations for Mesa Laboratories, Inc. (MLAB) for FY2026, with the revenue forecasts being adjusted by -0.51% over the past three months. During the same period, the stock price has changed by 19.15%.
Revenue Estimates for FY2026
Revise Downward
down Image
-0.51%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+9.89%
In Past 3 Month
Stock Price
Go Up
up Image
+19.15%
In Past 3 Month
Wall Street analysts forecast MLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLAB is 115.00 USD with a low forecast of 115.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast MLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLAB is 115.00 USD with a low forecast of 115.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 77.150
sliders
Low
115.00
Averages
115.00
High
115.00
Current: 77.150
sliders
Low
115.00
Averages
115.00
High
115.00
Jefferies
Tycho Peterson
Buy
maintain
$110 -> $115
2025-11-07
Reason
Jefferies
Tycho Peterson
Price Target
$110 -> $115
2025-11-07
maintain
Buy
Reason
Jefferies analyst Tycho Peterson raised the firm's price target on Mesa Labs to $115 from $110 and keeps a Buy rating on the shares following a Q2 report that were "solid" and "a relatively less noisy showing than 1Q results." The firm sees scope for shares to re-rate higher as stability comes back and credibility builds, the analyst tells investors.
Wells Fargo
Underweight -> Equal Weight
upgrade
$100 -> $67
2025-08-07
Reason
Wells Fargo
Price Target
$100 -> $67
2025-08-07
upgrade
Underweight -> Equal Weight
Reason
Wells Fargo upgraded Mesa Labs to Equal Weight from Underweight with a price target of $67, down from $100. The firm believes the recent sharp stock selloff appears overdone in the context of relatively stable fundamentals and clear balance sheet flexibility for Mesa Labs to redeem its outstanding converts due next week. Wells sees a more balanced risk/reward here at about 8-times EBITDA.
Wells Fargo
Brandon Couillard
Underweight
downgrade
$120 -> $100
2025-05-30
Reason
Wells Fargo
Brandon Couillard
Price Target
$120 -> $100
2025-05-30
downgrade
Underweight
Reason
Wells Fargo analyst Brandon Couillard lowered the firm's price target on Mesa Labs to $100 from $120 and keeps an Underweight rating on the shares. The firm notes Q4 revenues were in line, but adjusted EBITDA missed by about $2M, driven by higher-than-expected bonus accrual. Shares traded sharply lower, which Wells attributes to weak Q4 margins.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Mesa Laboratories Inc (MLAB.O) is 59.12, compared to its 5-year average forward P/E of 32.32. For a more detailed relative valuation and DCF analysis to assess Mesa Laboratories Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PE
32.32
Current PE
59.12
Overvalued PE
49.16
Undervalued PE
15.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
19.60
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
26.66
Undervalued EV/EBITDA
12.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.38
Current PS
0.00
Overvalued PS
6.88
Undervalued PS
1.89
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MLAB News & Events

Events Timeline

(ET)
2025-11-06
16:44:20
Mesa Labs announces Q2 earnings per share of 45 cents, down from 63 cents a year ago.
select
2025-09-22 (ET)
2025-09-22
04:55:00
S&P Dow Jones Indices Reveals Quarterly Rebalancing Update
select
2025-09-05 (ET)
2025-09-05
17:29:12
S&P Dow Jones Indices Reveals Quarterly Rebalancing Update
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
12-04Newsfilter
PinnedMesa Laboratories Schedules Q3 FY2026 Financial Results Release
  • Earnings Release Schedule: Mesa Laboratories plans to release its Q3 FY2026 financial results on February 3, 2026, at 8:00 A.M. ET, demonstrating the company's commitment to transparency and investor communication.
  • Industry Leadership: As a global leader in life science tools and critical quality control solutions, Mesa provides essential products in the pharmaceutical, healthcare, and medical device sectors, ensuring product integrity and enhancing patient and worker safety.
  • Customer Service Commitment: Mesa is dedicated to improving quality of life worldwide through its products and services, reflecting the company's strategic goal of meeting customer needs and raising industry standards.
  • Executive Contact Information: CEO Gary Owens and CFO John Sakys can be reached at 303-987-8000, further enhancing communication channels with investors and stakeholders.
[object Object]
Preview
9.5
12-04Globenewswire
Mesa Laboratories to Release Q3 FY2026 Financial Results on February 3, 2026
  • Earnings Release Schedule: Mesa Laboratories is set to announce its Q3 FY2026 financial results on February 3, 2026, at 8:00 A.M. ET, which will provide investors with critical performance data to assess the company's financial health.
  • Industry Leadership: As a global leader in the design and manufacture of life science tools and critical quality control solutions, Mesa serves the pharmaceutical, healthcare, and medical device industries, aiming to ensure product integrity and enhance patient and worker safety.
  • Customer Value Enhancement: Mesa's products and services not only help clients improve product quality but also focus on enhancing the quality of life worldwide, reflecting the company's significance and impact within the industry.
  • Management Contact Information: CEO Gary Owens and CFO John Sakys are available for contact, further enhancing communication with investors to ensure transparency and trust.
[object Object]
Preview
1.0
11-13Yahoo Finance
Mesa Laboratories, Inc. Set to Attend Upcoming Investor Conferences

  • Upcoming Conferences: Mesa Laboratories, Inc. executives Gary Owens and John Sakys will attend the Raymond James Napa Valley Small Cap Symposium on November 17, 2025, and the Jefferies London Healthcare Conference on November 20, 2025, featuring a fireside chat.

  • Webcast Availability: The Jefferies London Healthcare Conference fireside chat will be available via live webcast, with a replay accessible on Mesa Lab’s Investor Relations website.

  • Company Overview: Mesa Laboratories is a leader in designing and manufacturing life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device industries.

  • Contact Information: For inquiries, Mesa Laboratories can be contacted through CEO Gary Owens or CFO John Sakys at their provided phone number and email address.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Mesa Laboratories Inc (MLAB) stock price today?

The current price of MLAB is 77.15 USD — it has increased 1.01 % in the last trading day.

arrow icon

What is Mesa Laboratories Inc (MLAB)'s business?

Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.

arrow icon

What is the price predicton of MLAB Stock?

Wall Street analysts forecast MLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLAB is 115.00 USD with a low forecast of 115.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Mesa Laboratories Inc (MLAB)'s revenue for the last quarter?

Mesa Laboratories Inc revenue for the last quarter amounts to 60.74M USD, increased 5.02 % YoY.

arrow icon

What is Mesa Laboratories Inc (MLAB)'s earnings per share (EPS) for the last quarter?

Mesa Laboratories Inc. EPS for the last quarter amounts to 0.45 USD, decreased -28.57 % YoY.

arrow icon

What changes have occurred in the market's expectations for Mesa Laboratories Inc (MLAB)'s fundamentals?

The market is revising Downward the revenue expectations for Mesa Laboratories, Inc. (MLAB) for FY2026, with the revenue forecasts being adjusted by -0.51% over the past three months. During the same period, the stock price has changed by 19.15%.
arrow icon

How many employees does Mesa Laboratories Inc (MLAB). have?

Mesa Laboratories Inc (MLAB) has 730 emplpoyees as of December 05 2025.

arrow icon

What is Mesa Laboratories Inc (MLAB) market cap?

Today MLAB has the market capitalization of 426.05M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free